Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) announced that it has entered into a license...
SHE: 002940
Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...
Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...
Beijing Sun-Novo and Zhejiang Anglikang Deepen Ties with New Drug Development Partnership
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has...
Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...